Clinical Trials Logo

Mucopolysaccharidosis III clinical trials

View clinical trials related to Mucopolysaccharidosis III.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06181136 Recruiting - Clinical trials for Mucopolysaccharidosis Type IIIA

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Start date: December 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months) and is followed by a 72-week (approximately 18 month) open-label extension (OLE).

NCT ID: NCT06095388 Recruiting - Clinical trials for Mucopolysaccharidosis III-A

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Start date: October 4, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.

NCT ID: NCT06036693 Recruiting - Clinical trials for Mucopolysaccharidosis II

MPS (RaDiCo Cohort) (RaDiCo-MPS)

Start date: December 20, 2017
Phase:
Study type: Observational

The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.

NCT ID: NCT05705674 Recruiting - Sanfilippo Syndrome Clinical Trials

The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)

Start date: May 1, 2023
Phase:
Study type: Observational

The natural history study of patients with Sanfilippo disease(s) (MPS3)

NCT ID: NCT05523206 Recruiting - Clinical trials for Mucopolysaccharidosis III-A

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

Start date: September 27, 2022
Phase:
Study type: Observational

This protocol is a decentralized, single cohort, natural history and biomarker study enrolling up to 20 participants with MPS IIIA (Sanfilippo syndrome). At least 10 participants (~50%) must be less than four years old at the time of the Parent/LAR consent. The study will have a screening process and 7 study visits, e.g. home visits, that will consist of serum collection and completion of a remote assessment of the Vineland Adaptive Behavior Scales 3rd Edition (Vineland-3) MPS IIIA remains a devastating disease with a high unmet medical need. There is currently a limited number of available data to adequately characterize the progression of the disease. Analysis of blood biospecimens and adaptive behavior in this study will help researchers better understand the clinical progression of MPS IIIA. A better understanding of disease progression may assist in developing novel therapies for rare genetic disorders.